Literature DB >> 22679117

Neuroendocrine tumors.

Matthew H Kulke1, Al B Benson, Emily Bergsland, Jordan D Berlin, Lawrence S Blaszkowsky, Michael A Choti, Orlo H Clark, Gerard M Doherty, James Eason, Lyska Emerson, Paul F Engstrom, Whitney S Goldner, Martin J Heslin, Fouad Kandeel, Pamela L Kunz, Boris W Kuvshinoff, Jeffrey F Moley, Venu G Pillarisetty, Leonard Saltz, David E Schteingart, Manisha H Shah, Stephen Shibata, Jonathan R Strosberg, Jean-Nicolas Vauthey, Rebekah White, James C Yao, Deborah A Freedman-Cass, Mary A Dwyer.   

Abstract

Neuroendocrine tumors comprise a broad family of tumors, the most common of which are carcinoid and pancreatic neuroendocrine tumors. The NCCN Neuroendocrine Tumors Guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine tumors. Most of the recommendations pertain to well-differentiated, low- to intermediate-grade tumors. This updated version of the NCCN Guidelines includes a new section on pathology for diagnosis and reporting and revised recommendations for the surgical management of neuroendocrine tumors of the pancreas.

Entities:  

Mesh:

Year:  2012        PMID: 22679117     DOI: 10.6004/jnccn.2012.0075

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  68 in total

1.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.

Authors:  Meredith Cummins; Nick Pavlakis
Journal:  Ther Adv Med Oncol       Date:  2013-09       Impact factor: 8.168

3.  Are targeted therapies a consideration in poorly differentiated neuroendocrine tumors?

Authors:  Steven Sorscher
Journal:  Oncologist       Date:  2013

4.  Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.

Authors:  Matthew H Kulke; Al B Benson; Arvind Dasari; Lynn Huynh; Beilei Cai; Todor Totev; Nina Roesner; Mei Sheng Duh; Maureen P Neary; Victoria E Maurer; Brandon E Shih; Cecile G Dagohoy; Jennifer Chan; Emily K Bergsland
Journal:  Oncologist       Date:  2019-01-03

5.  Surveillance strategy for rectal neuroendocrine tumors according to recurrence risk stratification.

Authors:  Dong Hyun Kim; Jin Ha Lee; Yoon Jin Cha; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Hoguen Kim; Won Ho Kim; Sung Pil Hong
Journal:  Dig Dis Sci       Date:  2013-12-10       Impact factor: 3.199

6.  Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient.

Authors:  Manuel Weber; Lukas Kessler; Benedikt Schaarschmidt; Wolfgang Peter Fendler; Harald Lahner; Gerald Antoch; Lale Umutlu; Ken Herrmann; Christoph Rischpler
Journal:  BMC Cancer       Date:  2020-04-16       Impact factor: 4.430

Review 7.  Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

8.  Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus.

Authors:  Marianne Pavel; Nicole Unger; Ivan Borbath; Sergio Ricci; Tsann-Long Hwang; Thomas Brechenmacher; Jinhee Park; Fabian Herbst; Jennifer L Beaumont; Oliver Bechter
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

9.  Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.

Authors:  Jonathan R Strosberg; Al B Benson; Lynn Huynh; Mei Sheng Duh; Jamie Goldman; Vaibhav Sahai; Alfred W Rademaker; Matthew H Kulke
Journal:  Oncologist       Date:  2014-08-05

10.  Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.

Authors:  Epameinondas Dogeas; Georgios Karagkounis; Christopher M Heaphy; Kenzo Hirose; Timothy M Pawlik; Christopher L Wolfgang; Alan Meeker; Ralph H Hruban; John L Cameron; Michael A Choti
Journal:  J Am Coll Surg       Date:  2014-01-10       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.